LOC728591 Inhibitors
CCDC169, which stands for "Coiled-Coil Domain Containing 169," is a protein encoded by the gene with the same name. As indicated by its name, this protein is characterized by the presence of a coiled-coil domain, a structural motif that often mediates protein-protein interactions and is involved in a variety of cellular functions.
The coiled-coil domain is typically composed of alpha-helices that wind around each other to form a supercoil structure. This motif is known to play roles in the formation of cytoskeletal structures, vesicle trafficking, and the assembly of multiprotein complexes, suggesting that CCDC169 may similarly be involved in these or related cellular activities.The expression pattern of CCDC169 can provide clues to its function. If it has tissue-specific or developmentally regulated expression, it might suggest a specialized role in certain cell types or during specific stages of growth or differentiation. Furthermore, any association of the CCDC169 gene with disease states, either through mutation or altered expression levels, could offer insights into its functional importance in health and disease.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits phosphodiesterases, preventing cAMP breakdown, which may increase PKA activity and subsequently enhance the activity of CCDC169. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG, a kinase inhibitor, could reduce competitive kinase activity, potentially allowing CCDC169's pathways to be less inhibited and thus more active. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P modulates lipid signaling, which could indirectly enhance the functional activity of CCDC169 by influencing pathways it is involved in. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates PKC, which could phosphorylate and enhance the functional activity of CCDC169 through downstream signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, potentially altering signaling pathways to enhance CCDC169 functional activity indirectly by modulating related pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, could lead to alterations in cellular signaling that indirectly enhance the functional role of CCDC169. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, potentially shifting signaling pathways to indirectly enhance CCDC169 functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which could lead to an enhancement of CCDC169 activity by modulating related signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, may allow signaling pathways involving CCDC169 to be more active by reducing competitive kinase signaling. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin increases intracellular calcium levels, which may activate calcium-dependent signaling pathways, potentially enhancing CCDC169 activity. | ||||||